Activation of the EGF receptor (EGFR)/MAPK pathway was also observed in the cPLS liver disease model in an etiology-independent manner, as shown by enhanced EGFR phosphorylation (Supplemental Figure 2A), upregulation of EGF/EGFR expression (Supplemental Figure 2B), and induction of experimentally defined EGF target gene signatures (22, 23) (Supplemental Figure 2C). The gene discussed is EGFR; the disease is liver disorder.